Accessibility Menu
Annexon Stock Quote

Annexon (NASDAQ: ANNX)

$2.96
(-1.5%)
-0.04
Price as of October 23, 2025, 2:02 p.m. ET

KEY DATA POINTS

Current Price
$2.96
Daily Change
(-1.5%) $0.04
Day's Range
$2.91 - $3.05
Previous Close
$3
Open
$2.99
Beta
1.05
Volume
635,891
Average Volume
1,669,797
Market Cap
329.7M
Market Cap / Employee
$3.00M
52wk Range
$1.29 - $7.64
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$1.29
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Annexon Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ANNX-60.37%-87.73%-34.26%-83%
S&P+14.5%+93.32%+14.09%+108%

Annexon Company Info

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.91M-6.5%
Market Cap$263.31M-49.0%
Market Cap / Employee$2.56M0.0%
Employees1030.0%
Net Income-$49.16M-66.0%
EBITDA-$50.81M-55.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$132.29M-15.9%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$24.91M-10.6%
Short Term Debt$2.72M15.8%

Ratios

Q2 2025YOY Change
Return On Assets-55.74%-19.7%
Return On Invested Capital-42.56%8.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$38.09M-75.4%
Operating Free Cash Flow-$38.07M-75.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.731.640.721.08-36.07%
Price to Tangible Book Value1.731.640.721.08-36.07%
Enterprise Value to EBITDA-13.43-9.21-0.89-3.08-66.29%
Return on Equity-48.1%-50.8%-66.1%-66.7%58.18%
Total Debt$29.61M$28.97M$28.31M$27.63M-8.52%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.